WHO tests new drugs against COVID-19 also in Portugal

According to information from the World Health Organization, three drugs will be tested to treat patients with COVID-19. Clinical trials will take place in 52 countries and Portugal is on the list.

The director of WHO warned that in the next year 300 million infected with SARS-COV-2 could be registered.

Clinical drug trials in nearly 600 hospitals...

According to what has been revealed, the tests are part of the new phase of the WHO Solidarity clinical trial, which enters the Solidarity Plus phase to test the effectiveness of the drugs artesunate (from the pharmaceutical laboratory IPCA), used to treat severe cases of malaria; imatinib (Novartis), used to treat some types of cancer; and infliximab (Johnson and Johnson), used to treat immune system disorders such as rheumatoid arthritis.

WHO tests new drugs against COVID-19 also in Portugal

The WHO communiqué also states that in new phase of clinical trials with drugs involved around 600 hospitals in 52 participating countries, 16 more countries than in the initial phase, and it is possible to assess the effectiveness of multiple treatments at the same time using a single protocol, recruiting thousands of patients to generate robust estimates of the effectiveness that a drug can have on mortality.

The protocol also allows for the addition of new drugs throughout the process and the abandonment of those considered ineffective. The tests have already allowed to demonstrate, for example, that medications such as remdesivir, hydroxychloroquine, lopinavir and interferon have little or no efficacy in hospitalized patients.

The clinical drug trial will only recruit adult patients, male and female, in hospital until May 1, 2022.

As we know, the vaccine against COVID-19 is a way to prevent the severe form of the disease, but it does not prevent infection. According to recent information, there are several drugs to be developed, among which the drug developed by the Sourasky Medical Center in Tel Aviv, Israel stands out, and it was tested on patients at various hospitals in Athens, Greece.